395101-67-4

Usage

Uses

Used in Pharmaceutical Research:
3-Bromo-5-Cyano (1H)Indazole is used as a key intermediate in the synthesis of potential pharmaceuticals. Its unique structure allows for the development of new drugs with improved therapeutic properties, such as enhanced efficacy, selectivity, and reduced side effects.
Used in Agrochemical Research:
In the agrochemical industry, 3-Bromo-5-Cyano (1H)Indazole serves as a building block for the creation of novel agrochemicals. Its incorporation into the molecular structures of these compounds can lead to the development of more effective and environmentally friendly pesticides, herbicides, and other agricultural chemicals.
Used in Materials Science Research:
3-Bromo-5-Cyano (1H)Indazole is utilized in materials science research for the development of new materials with unique properties. Its versatile structure can contribute to the creation of advanced materials for various applications, such as electronics, energy storage, and sensing technologies.
Used in Heterocyclic Chemistry Studies:
3-Bromo-5-Cyano (1H)Indazole is employed as a valuable tool in the study of heterocyclic chemistry. Its unique structure and properties provide insights into the reactivity, stability, and potential applications of heterocyclic compounds, contributing to the advancement of this field of research.

InChI:InChI=1/C8H4BrN3/c9-8-6-3-5(4-10)1-2-7(6)11-12-8/h1-3H,(H,11,12)

Upstream product

• 74626-47-4 1H-indazole-5-carbonitrile 
• 146137-79-3 4-fluoro-3-formylbenzonitrile 

Downstream Products

• 473416-06-7 tert-butyl 3-bromo-5-cyano-1H-1-indazolecarboxylate 
• 395101-69-6 3-bromo-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole-5-carbonitrile 
• 1374353-12-4 C₅₇H₅₁BrN₆O₂ 
• 1374353-11-3 (R)-tert-butyl 3-(3-(3-bromo-1-trityl-1H-indazol-5-yl)-1H-1,2,4-triazol-5-yl)piperidine-1-carboxylate 
• 1374353-13-5 (R)-tert-butyl 3-(3-(3-(pyridin-4-yl)-1-trityl-1H-indazol-5-yl)-1H-1,2,4-triazol-5-yl)piperidine-1-carboxylate 
• 1374351-11-7 (R)-5-(5-(1-(2-fluoro-6-methoxybenzyl)piperidin-3-yl)-1H-1,2,4-triazol-3-yl)-3-(pyridin-4-yl)-1H-indazole 
• 1374351-13-9 (R)-5-(5-(1-(2-fluoro-6-methoxybenzyl)piperidin-3-yl)-1-methyl-1H-1,2,4-triazol-3-yl)-3-(pyridin-4-yI)-1H-indazole 

Relevant academic research and scientific papers

EGFR INHIBITOR, AND PREPARATION AND APPLICATION THEREOF

A 4-substituted-2-(N-(5-substituted allyl amide)phenyl)amino)pyrimidine derivative as represented by formula (I), and a preparation and application thereof as an EGFR inhibitor. The compound has activity of inhibiting the L858R EGFR mutant, the T790M EGFR mutant and the exon 19 deletion activating mutant, may be used to treat diseases mediated alone or in part by EGFR mutant activity, and has a wide application in drugs preventing and treating cancers, particularly non-small cell lung cancer.

Compounds as syk kinase inhibitors

The present invention relates to a compound of formula (I), to the process for preparing such compounds and to their use in the treatment of a pathological condition or disease susceptible to amelioration by inhibition of Syk kinase.

Indazole compounds, compositions thereof and methods of treatment therewith

This invention is generally directed to the use of Indazole Compounds for treating or preventing diseases associated with protein kinases, including tyrosine kinases, such as proliferative diseases, inflammatory diseases, abnormal angiogenesis and diseases related thereto, atherosclerosis, macular degeneration, diabetes, obesity, pain and others. The methods comprise the administration to a patient in need thereof of an effective amount of an indazole compound that inhibits, modulates or regulates tyrosine kinase signal transduction. Novel indazole compounds or pharmaceutically acceptable salt thereof are presented herein.

Methods for treating an inflammatory condition or inhibiting JNK

This invention is generally directed to Indazole Derivatives having the following structure: 1 or pharmaceutically acceptable salt thereof, wherein R1, R2 and A are as defined herein. Such compounds have utility in the treatment of a wide range of diseases and disorders that are responsive to JNK inhibition, such as an inflammatory disease or disorder. Thus, methods of treating such diseases and disorders are also disclosed, as are pharmaceutical compositions containing one or more compounds of the above compounds.

NOVEL 1H-INDAZOLE COMPOUND

The present invention provides a novel 1H-indazole compound having an excellent JNK inhibitory action. More specifically, it provides a compound represented by the following formula, a salt thereof or a hydrate of them. Wherein R1 is a C6-C14 aromatic cyclic hydrocarbon group etc.; R2, R4 and R5 each independently represent a hydrogen atom, a halogen atom, a cyano group etc.; L is a single bond, or a C1-C6 alkylene group etc.; X is a single bond, or a group represented by -CO-NH- or -NH-CO-, etc.; and Y is a C3-C8 cycloalkyl group, a C6-C14 aromatic cyclic hydrocarbon group or a 5- to 14-membered aromatic heterocyclic group etc.

Indazole derivatives as JNK inhibitors and compositions and methods related thereto

Compounds having activity as selective inhibitors of JNK are disclosed. The compounds of this invention are indazole derivatives having the following structure: wherein R1, R2 and A are as defined herein. Such compounds have utility in the treatment of a wide range of conditions that are responsive to JNK inhibition. Thus, methods of treating such conditions are also disclosed, as are pharmaceutical compositions containing one or more compounds of the above compounds.